The chemical modification of natural compounds is a promising strategy to improve their frequently poor bioavailability and low potency. This study aimed at synthesizing chemical derivatives of carvone, a natural monoterpene with anti-inflammatory properties, which we recently identified, and evaluating their potential anti-inflammatory activity. Fourteen chemical derivatives of carvone were synthesized, purified and their chemical structures confirmed. Noncytotoxic concentrations of the test compounds were selected based on the resazurin reduction assay. Among the tested compounds, four significantly reduced the lipopolysaccharides-induced protein levels of the inducible isoform of the nitric oxide synthase and nitric oxide production and showed a dual effect on pro-IL-1 protein levels in the Raw 264.7 cell line. The Ligand Express drug discovery platform was used to predict the targets of the test compounds, and an enrichment analysis was performed to group the different biological processes and molecular and cellular functions of the tested compounds. Moreover, Ligand Express also predicted that all chemicals evaluated have intestinal and blood–brain barrier permeability, do not inhibit P-gp and do not interact with major receptors. Although presenting anti-inflammatory and some advantageous ADME properties, the tested compounds still have low potency and specificity but may provide novel structures the further chemical modification of which may yield more promising drugs.
1 April 2021 in The Journal of Chemical Thermodynamics
Pancreatic cancer (PC) is one of the malignancies with the lowest survival rate, mainly due to its late detection, a hostile tumor environment, and the low efficacy of currently approved therapies. To address these limitations, nanotechnology has been explored to develop innovative drug delivery strategies for PC therapy. This review aims to provide an overview of existing lipid-based nanosystems for the treatment of PC, including liposomes, nanoemulsions, solid lipid nanoparticles, nanostructured lipid carriers, and lipid-polymer hybrid nanoparticles. These systems are generally characterized by their biodegradability, biocompatibility, drug protection ability, potential to encapsulate multiple drugs, and specific targeting to the affected tissue, thereby reducing side effects. Preclinical studies have shown promising results in the treatment of PC. However, clinical trials for these new formulations are still in their early stages, with liposomes being the primary focus of the scientific community. The challenging transition between the preclinical and clinical phases is associated with difficulties in replicating in vitro results and scaling up these nanosystems. Despite the significant progress made to date, further research and the standardization of regulations are still needed to make the approval process for lipid-based nanosystems more efficient.